To explore the potential clinical impact of altered 5hmC levels in GBM, we examined the relationships between TET expression and patient outcomes and found across multiple clinical datasets that low TET2 expression correlates with poor survival (Fig. 1a and Supplementary Fig. 1). This evidence concerns the gene TET2 and glioblastoma.